-
Investors who purchased shares of Loxo Oncology, Inc. (NASDAQ: LOXO) and currently hold any of those NASDAQ: LOXO shares have certain options and should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
An investigation on behalf of investors, who currently hold shares of Loxo Oncology, Inc. (NASDAQ: LOXO), was announced concerning whether the takeover of Loxo Oncology, Inc. is unfair to NASDAQ: LOXO stockholders.
The investigation by a law firm concerns whether certain officers and directors of Loxo Oncology, Inc. breached their fiduciary duties owed to NASDAQ: LOXO investors in connection with the proposed acquisition.
On Jan. 07, 2019, Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) announced an agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash.
However, the investigation concerns whether the offer is unfair to NASDAQ: LOXO stockholders. More specifically, the investigation concerns whether the Loxo Oncology Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Shares of Loxo Oncology, Inc. (NASDAQ: LOXO) closed on January 11, 2019, at $232.51 per share.
